A New York federal judge on Friday recommended certifying two classes of direct purchasers and end payors in consolidated antitrust actions against Takeda Pharmaceuticals Co. The plaintiffs accuse the pharmaceutical giant of unlawfully inflating the price of its diabetes treatment Actos by delaying the entry of generic alternatives. This decision marks a significant step in the legal proceedings surrounding the allegations that Takeda implemented anticompetitive practices.
For more detailed information, you can read the original coverage here.